Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RCKT Rocket Pharmaceuticals, Inc.

交易中 09-29 12:01:43 EDT

2.59

-0.02

-0.78%

最高2.65	最低2.58	成交量48.71万
今开2.63	昨收2.61	日振幅2.53%
总市值2.84亿	流通市值2.21亿	总股本1.10亿
成交额127.02万	换手率0.57%	流通股本8,539万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RCKT","market":"US","secType":"STK","nameCN":"Rocket Pharmaceuticals, Inc.","latestPrice":2.5897,"timestamp":1790697676483,"preClose":2.61,"halted":0,"volume":487067,"delay":0,"changeRate":-0.007777777777777687,"floatShares":85391465,"shares":109774597,"eps":-0.17,"marketStatus":"交易中","change":-0.0203,"latestTime":"09-29 12:01:43 EDT","open":2.63,"high":2.646,"low":2.58,"amount":1270161.3407518,"amplitude":0.025287,"askPrice":2.59,"askSize":1600,"bidPrice":2.58,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-0.17,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790712000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1424235600000,"exchange":"NASDAQ","adjPreClose":2.61,"preHourTrading":{"tag":"盘前","latestPrice":2.63,"preClose":2.61,"latestTime":"09:29 EDT","volume":6510,"amount":17128.947948,"timestamp":1790688599918,"change":0.02,"changeRate":0.007663,"amplitude":0.068966},"postHourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.61,"latestTime":"19:49 EDT","volume":22559,"amount":59030.366,"timestamp":1790639386989,"change":-0.01,"changeRate":-0.003831,"amplitude":0.02682},"volumeRatio":0.48255,"impliedVol":1.0764,"impliedVolPercentile":0.1315},"requestUrl":"/m/hq/s/RCKT","defaultTab":"news","newsList":[{"id":"1148235584","title":"Rocket Pharmaceuticals宣布与FDA达成一致，推进Danon病领域Rp-A501关键性II期临床试验完成路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1148235584","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148235584?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:02","pubTimestamp":1789470155,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc.今日宣布，已与美国食品药品监督管理局就完成其在Danon病治疗领域主打候选药物Rp-A501的关键性II期临床试验的路径达成了共识。通过此次与监管机构的积极且富有建设性的沟通，Rocket Pharmaceuticals有望更清晰地界定并执行其临床策略，从而加速评估Rp-A501的安全性及有效性。此次公布的利好动态，也进一步巩固了Rocket Pharmaceuticals在罕见病基因治疗领域的领先地位，为其研发管线的持续进展注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118259996","title":"Rocket Pharmaceuticals：FDA确认12个月共同主要终点，或为加速批准铺平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1118259996","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118259996?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:01","pubTimestamp":1789470071,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc.传来重磅消息——美国食品药品监督管理局已正式确认，其潜在加速批准路径所依托的12个月共同主要终点指标获得认可。据悉，此次FDA的确认决定，围绕Rocket Pharmaceuticals所提议的、以12个月为评估窗口的共同主要终点展开。业内观察人士指出，这一动态不仅凸显了FDA对创新疗法的灵活审评态度，也反映出Rocket Pharmaceuticals在临床开发策略上的精准布局。值得注意的是，FDA的确认并不等同于批准本身，后续仍需依赖实际临床结果的支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124821603","title":"Rocket Pharmaceuticals 现金及投资约2.837亿美元，预计资金跑道可延至2028年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1124821603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124821603?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:49","pubTimestamp":1786394989,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 披露其现金、现金等价物及投资总额约为2.837亿美元。基于这一财务储备，公司预期其现有资金将足以支撑运营至2028年的第二季度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146191818","title":"Rocket Pharmaceuticals 公布改良版Danon病2期临床试验中首批三名患者接受Rp-A501治疗的积极安全性更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1146191818","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146191818?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:06","pubTimestamp":1785755161,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 宣布，基于改良版2期临床试验方案，首批接受Rp-A501治疗的三名Danon病患者，其临床安全性数据呈现积极态势。此次更新标志着该试验取得了阶段性进展，为后续研究奠定了坚实基础。公司管理层对此次结果表示审慎乐观，并强调将持续监测患者长期安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107893250","title":"Rocket Pharmaceuticals：Rp-A501在首批三名患者中耐受性良好，未出现TMA或毛细血管渗漏综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1107893250","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107893250?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:02","pubTimestamp":1785754955,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals公司宣布，其候选药物Rp-A501在首批三名患者中表现出良好的耐受性。值得关注的是，在这项初步研究中，没有观察到血栓性微血管病（TMA）或毛细血管渗漏综合征的发生。这一结果标志着该药物在安全性方面迈出了积极的一步，为后续临床开发提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108020187","title":"Rocket Pharmaceuticals以1.8亿美元完成罕见儿科疾病优先审评券出售交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1108020187","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108020187?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:01","pubTimestamp":1781262078,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, Inc. 已成功完成其罕见儿科疾病优先审评券的出售，交易总额为1.8亿美元。此举将为公司带来可观的非稀释性资金，用于推进其针对严重罕见疾病的基因治疗产品管线的研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119497721","title":"FDA向罕见儿科疾病产品申请方颁发优先审评券——联邦公报网站","url":"https://stock-news.laohu8.com/highlight/detail?id=1119497721","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119497721?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:50","pubTimestamp":1775047827,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式向一项罕见儿科疾病产品申请的赞助商授予优先审评凭证。这一重要公告发布在联邦公报官方网站上。\n优先审评券计划旨在激励制药企业针对罕见儿科疾病开发创新疗法。获得此凭证的申办方可在后续药物审评中享受加速审评流程的权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517043028","title":"Rocket Pharmaceuticals, Inc.2024财年实现净利润-2.59亿美元，同比减少5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517043028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517043028?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Rocket Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.59亿美元，同比减少5.28%；其中营业收入为0.00美元，每股基本收益为-2.73美元。从资产负债表来看，Rocket Pharmaceuticals, Inc.总负债64.47百万美元，其中短期债务2.86百万美元，资产负债比为0.09，流动比率为0.10。机构评级：截至2025年3月8日，当前有14家机构对Rocket Pharmaceuticals, Inc.目标价做出预测，其中目标均价为39.86美元，其中最低目标价为15.00美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000226abed6696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000226abed6696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517427639","title":"Rocket Pharmaceuticals, Inc.盘中异动 急速上涨5.02%报9.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517427639","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517427639?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:23","pubTimestamp":1741195422,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时23分，Rocket Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.02%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为934.29%、303.67%、291.71%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012342a260f792&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012342a260f792&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668785","title":"Rocket Pharmaceuticals, Inc.盘中异动 下午盘快速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668785?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:09","pubTimestamp":1741032562,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时09分，Rocket Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.03%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4586.34%、212.52%、182.79%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040922abe690da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040922abe690da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516374506","title":"Scotiabank：维持Rocket Pharmaceuticals(RCKT.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由51.00美元调整至52.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516374506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516374506?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Rocket Pharmaceuticals(RCKT.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由51.00美元调整至52.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516742638","title":"加拿大投资银行集团：维持Rocket Pharmaceuticals(RCKT.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至36.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516742638","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516742638?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:41","pubTimestamp":1741005705,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：维持Rocket Pharmaceuticals(RCKT.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至36.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03204148492500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514351191","title":"Rocket Pharmaceuticals(RCKT.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为3.13万美元；每股收益为-0.62美元，前值为-0.64美元，预期值为-0.72美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351191","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514351191?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:54","pubTimestamp":1740696868,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals(RCKT.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为3.13万美元；每股收益为-0.62美元，前值为-0.64美元，预期值为-0.72美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28065448442536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182675192","title":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益$(0.62)超预期$(0.71)","url":"https://stock-news.laohu8.com/highlight/detail?id=1182675192","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182675192?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692337,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益为$(0.62)，超出市场预期的$(0.71)。以上内容来自Benzinga Earnings专栏，原文如下：Rocket Pharmaceuticals Q4 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rocket Pharmaceuticals 2024年第四季度GAAP每股收益$(0.62)超预期$(0.71)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514180850","title":"Rocket Pharmaceuticals, Inc.盘中异动 临近午盘急速上涨5.02%报9.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180850","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514180850?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:37","pubTimestamp":1740587835,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时37分，Rocket Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.02%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5902.90%、215.43%、213.88%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Organovo Holdings, Inc.，振幅分别为181.36%、49.18%、43.31%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270037159893c268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270037159893c268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514501900","title":"Rocket Pharmaceuticals, Inc.盘中异动 早盘大幅下跌5.07%报9.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514501900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514501900?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:20","pubTimestamp":1740500401,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时20分，Rocket Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.07%。截至发稿，该股报9.54美元/股，成交量33.6616万股，换手率0.32%，振幅6.07%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1320.96%、1114.08%、897.28%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002001a2539fbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226002001a2539fbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509781357","title":"Rocket Pharmaceuticals, Inc.盘中异动 临近收盘大幅下挫5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509781357?lang=zh_cn&edition=full","pubTime":"2025-02-07 04:54","pubTimestamp":1738875275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日04时54分，Rocket Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.16%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Ocean Biomedical, Inc.较为活跃，换手率分别为7114.19%、1779.44%、202.65%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为125.58%、77.86%、65.64%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045436abc51ee1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045436abc51ee1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509549506","title":"Rocket Pharmaceuticals, Inc.盘中异动 大幅拉升5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509549506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509549506?lang=zh_cn&edition=full","pubTime":"2025-02-05 03:59","pubTimestamp":1738699186,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日03时59分，Rocket Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.40%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.56%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028、Mink Therapeutics, Inc.涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1926.22%、986.35%、586.25%，振幅较大的相关个股有Azitra Inc、Omega Therapeutics, Inc.、Mink Therapeutics, Inc.，振幅分别为123.99%、59.42%、58.27%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205035946a2396553&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205035946a2396553&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149757","title":"Rocket Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.03%报10.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149757","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149757?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:35","pubTimestamp":1738593351,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时35分，Rocket Pharmaceuticals, Inc.股票出现波动，股价快速跳水5.03%。截至发稿，该股报10.20美元/股，成交量4.4409万股，换手率0.04%，振幅2.51%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Briacell Therapeutics Corp.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为354.00%、308.13%、144.93%，振幅较大的相关个股有Hcw Biologics Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Invivyd, Inc.，振幅分别为57.23%、33.33%、27.90%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223551abc10828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223551abc10828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506303118","title":"Rocket Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506303118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506303118?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:42","pubTimestamp":1737988961,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时42分，Rocket Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.14%。Rocket Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，Akero Therapeutics, Inc.、89Bio, Inc.、Moolec Science Sa C/Wts 涨幅较大，Evaxion Biotech As、Pmgc Holdings Inc.、Hepion Pharmaceuticals, Inc.较为活跃，换手率分别为71.03%、58.66%、47.89%，振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Immatics N V C/Wts 01/07/2025 ，振幅分别为65.16%、53.97%、53.75%。Rocket Pharmaceuticals, Inc.公司简介：Rocket Pharmaceuticals Inc 是一家后期生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224241a2316d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224241a2316d63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rocketpharma.com","stockEarnings":[{"period":"1week","weight":-0.2018},{"period":"1month","weight":-0.3238},{"period":"3month","weight":-0.2368},{"period":"6month","weight":-0.279},{"period":"1year","weight":-0.1994},{"period":"ytd","weight":-0.2564}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rocket Pharmaceuticals, Inc.于1999年7月7日根据特拉华州法律注册成立。该公司是一家完全整合的、处于后期阶段的生物技术公司，专注于开发首创、唯一和同类最佳的基因疗法，具有直接的靶向作用机制和明确的临床终点，用于罕见和破坏性疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.061021},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020726},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.084731},{"month":4,"riseRate":0.583333,"avgChangeRate":0.010265},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.043149},{"month":6,"riseRate":0.583333,"avgChangeRate":0.004799},{"month":7,"riseRate":0.583333,"avgChangeRate":0.119654},{"month":8,"riseRate":0.5,"avgChangeRate":-0.009052},{"month":9,"riseRate":0.5,"avgChangeRate":0.061395},{"month":10,"riseRate":0.545455,"avgChangeRate":0.048247},{"month":11,"riseRate":0.545455,"avgChangeRate":0.014665},{"month":12,"riseRate":0.545455,"avgChangeRate":0.102516}],"exchange":"NASDAQ","name":"Rocket Pharmaceuticals, Inc.","nameEN":"Rocket Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rocket Pharmaceuticals, Inc.,RCKT,Rocket Pharmaceuticals, Inc.股票,Rocket Pharmaceuticals, Inc.股票老虎,Rocket Pharmaceuticals, Inc.股票老虎国际,Rocket Pharmaceuticals, Inc.行情,Rocket Pharmaceuticals, Inc.股票行情,Rocket Pharmaceuticals, Inc.股价,Rocket Pharmaceuticals, Inc.股市,Rocket Pharmaceuticals, Inc.股票价格,Rocket Pharmaceuticals, Inc.股票交易,Rocket Pharmaceuticals, Inc.股票购买,Rocket Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}